Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: A registry-based case-crossover study

American Journal of Epidemiology

Volumn 168, Issue 8, 2008, Pages 966-973

  Hallas, Jesper ^a   Bjerrum, Lars ^a   Støvring, Henrik ^a   Andersen, Morten ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Ephedra sinica; Ephedrine; Mortality; Myocardial infarction; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CAFFEINE; CAFFEINE PLUS EPHEDRINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; EPHEDRINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LETIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

BODY MASS; CARDIOVASCULAR DISEASE; DRUG USER; HEALTH RISK; MORTALITY; RISK ASSESSMENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CASE CROSSOVER TECHNIQUE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DENMARK; DIABETES MELLITUS; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MORTALITY; OBESITY; REGISTER; RISK ASSESSMENT; RISK FACTOR; STROKE;

ADOLESCENT; ADULT; AGED; ANTI-OBESITY AGENTS; CAFFEINE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DENMARK; DRUG COMBINATIONS; EPHEDRINE; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

NORTH AMERICA; UNITED STATES;

EPHEDRA; EPHEDRA SINICA;

EID: 53749106663     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn191     Document Type: Article

References (27)

1. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003;289(12):1537-1545.
2. Andraws R, Chawla P, Brown DL. Cardiovascular effects of ephedra alkaloids: a comprehensive review. Prog Cardiovasc Dis. 2005;47(4):217-225.
3. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000;343(25):1833-1838.
4. Food and Drug Administration. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Fed Reg. 2004;69(28):6787-6854.
5. Soni MG, Carabin IG, Griffiths JC, et al. Safety of ephedra: lessons learned. Toxicol Lett. 2004;150(1):97-110.
6. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997;44(4):445-448.
7. Danish Medicines Agency. Statistik for lægemidler og lægemiddelgrupper, 2003-2007 [in Danish]. Copenhagen, Denmark: Danish Medicines Agency, 2007. (www.medstat.dk/MedStatDataViewer.php) (Accessed March 20, 2008).
8. Frank L. When an entire country is a cohort. Science. 2000;287(5462):2398-2399.
9. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health. Guidelines for ATC Classification and DDD Assignment. Oslo, Norway: Norwegian Institute of Public Health; 2006.
10. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144-153.
11. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health. 2000;21:193-221.
12. Schneeweiss S, Sturmer T, Maclure M. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf. 1997;6(6 suppl 3):S51-S59.
13. Blanck HM, Khan LK, Serdula MK. Use of nonprescription weight-loss products: results from a multistate survey. JAMA. 2001;286(8):930-935.
14. Hallas J, Stovring H. Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol. 2006;98(3):260-265.
15. Suissa S. The case/time/control design. Epidemiology. 1995;6:248-253.
16. Gurley BJ, Wang P, Gardner SF. Ephedrine-type alkaloid content of nutritional supplements containing Ephedra sinica (ma-huang) as determined by high performance liquid chromatography. J Pharm Sci. 1998;87(12):1547-1553.
17. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343(25):1826-1832.
18. Morgenstern LB, Viscoli CM, Kernan WN, et al. Use of ephedra-containing products and risk for hemorrhagic stroke. Neurology. 2003;60(1):132-135.
19. Yoon BW, Bae HJ, Hong KS, et al. Phenylpropanolamine contained in cold remedies and risk of hemorrhagic stroke. Neurology. 2007;68:146-149.
20. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax. 2000;55(12):987-999.
21. Crawford D, Jeffery RW, French SA. Can anyone successfully control their weight? Findings of a three year community-based study of men and women. Int J Obes Relat Metab Disord. 2000;24(9):1107-1110.
22. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med. 1990;322(4):213-217.
23. Avenell A, Brown TJ, McGee MA, et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet. 2004;17(4):317-335.
24. Bjerrum L, Andersen M, Hallas J. Antibiotics active against Chlamydia do not reduce the risk of myocardial infarction. Eur J Clin Pharmacol. 2006;62(1):43-49.
25. Bak S, Tsiropoulos I, Kjærsgaard JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population based case-control study. Stroke. 2002;33(6):1465-1473.
26. Sørensen HT, Larsen BO. A population-based Danish data resource with possible high validity in pharmacoepidemiological research. J Med Syst. 1994;18(1):33-38.
27. International Narcotics Control Board, United Nations. Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report of the International Narcotics Control Board for 2005 on the Implementation of Article 12 of the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988. (Report E/INCB/2005/4). Vienna, Austria: International Narcotics Control Board; 2005:1-3. (http://www.incb.org/incb/en/precursors_2005.html).